Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2525)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5695)
  2. Department of Medicine (5685)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (203)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5695)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-GuĂ©rin (BCG)
    Meeting Abstract

    de Wit, R.; Kulkarni, G. S.; Uchio, E.; Boormans, J. L.; Roumiguie, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Albiges, L.; Rini, B. I.; Haanen, Jbag; Motzer, R. J.; Kollmannsberger, C. K.; Negrier, S.; Nole, F.; Bedke, J.; Bilen, M. A.; Nathan, P.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody
    Journal Article

    Carrasquillo, J. A.; Fine, B. M.; Pandit-Taskar, N.; Larson, S. M.; Fleming, S. E.; Fox, J. J.; Cheal, S. M.; O'Donoghue, J. A.; Ruan, S.; Ragupathi, G.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy
    Journal Article

    Rosenberg, J. E.; O'Donnell, P. H.; Balar, A. V.; McGregor, B. A.; Heath, E. I.; Yu, E. Y.; Galsky, M. D.; Hahn, N. M.; Gartner, E. M.; Pinelli, J. M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy
    Journal Article

    Feuerstein, M. A.; Goldstein, L.; Reaves, B.; Sun, A.; Goltzman, M.; Morganstern, B. A.; Shabsigh, A.; Bajorin, D. F.; Rosenberg, J. E.; Donat, S. M.; more...
    World Journal of Urology (2019)

    Fulltext@MSK | Save
  • Measuring the unmeasurable: Automated bone scan index as a quantitative endpoint in prostate cancer clinical trials
    Review

    Mota, J. M.; Armstrong, A. J.; Larson, S. M.; Fox, J. J.; Morris, M. J.
    Prostate Cancer and Prostatic Diseases (2019)

    Fulltext@MSK | Save
  • Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial
    Journal Article

    George, D. J.; Hessel, C.; Halabi, S.; Michaelson, M. D.; Hahn, O.; Walsh, M.; Picus, J.; Small, E. J.; Dakhil, S.; Feldman, D. R.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Towards individualized therapy for metastatic renal cell carcinoma
    Review

    Kotecha, R. R.; Motzer, R. J.; Voss, M. H.
    Nature Reviews Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: Phase 3 CALGB 80802 randomized clinical trial
    Journal Article

    Abou-Alfa, G. K.; Shi, Q.; Knox, J. J.; Kaubisch, A.; Niedzwiecki, D.; Posey, J.; Tan, B. R. Jr; Kavan, P.; Goel, R.; Lammers, P. E.; more...
    JAMA Oncology (2019)

    Fulltext@MSK | Save
  • Familial kidney cancer: Implications of new syndromes and molecular insights
    Review

    Carlo, M. I.; Hakimi, A. A.; Stewart, G. D.; Bratslavsky, G.; Brugarolas, J.; Chen, Y. B.; Linehan, W. M.; Maher, E. R.; Merino, M. J.; Offit, K.; more...
    European Urology (2019)

    Fulltext@MSK | Save